

# 1 **Role of Artificial Intelligence-Powered Conversational Agents (Chatbots) in** 2 **Musculoskeletal Disorders: A Scoping Review Protocol**

3  
4 Joaquín González Aroca\* <sup>1</sup>, Laura Vergara-Merino <sup>2</sup>, Camila Micaela Escobar Liquitay <sup>3</sup>  
5 Humberto Farías A <sup>4</sup>, Jorge Olivares Arancibia <sup>5</sup> and Álvaro Puelles <sup>1</sup>

6  
7 1 School of Kinesiology, Universidad de La Serena, La Serena, Chile  
8 2 Department of Traumatology and Orthopedics, Pontificia Universidad Católica de Chile,  
9 Chile.

10 3 Research Department, Instituto Universitario Hospital Italiano de Buenos Aires, Buenos  
11 Aires, Argentina

12 4 Department of Industrial Engineering, Universidad de La Serena, La Serena, Chile  
13 5 AFySE Group, Research in Physical Activity and School Health, School of Pedagogy in  
14 Physical Education, Faculty of Education, Universidad de las Américas, Santiago, Chile.

15  
16 \* Correspondence: [joaquin.gonzalez@userena.cl](mailto:joaquin.gonzalez@userena.cl)

17  
18 Word count: 1103

19 **Keywords:** Musculoskeletal Disorders; Artificial intelligence; Chatbot

20  
21 **Abstract**

22 **Introduction:** Musculoskeletal disorders (MSDs) represent a significant global health  
23 burden, leading to substantial disability and socioeconomic impact. With the rise of artificial  
24 intelligence (AI), particularly large language models-driven conversational agents  
25 (chatbots), there is potential to enhance the management of MSDs. However, the  
26 application of AI-powered chatbots in this population has not been comprehensively  
27 synthesized.

28  
29 **Objective:** To explore the current and potential use of AI-powered chatbots in the  
30 management of MSDs. The review will map out the targeted diseases, the purposes of  
31 chatbot interventions, the clinical tools or frameworks utilized in training these systems,  
32 and the evaluated outcomes in clinical settings.

33  
34 **Methods:** This scoping review will follow the PRISMA-ScR guidelines, with a comprehensive  
35 search across multiple databases including Medline (Ovid MEDLINE), Embase (Ovid), ISI  
36 Web of Science (wos; clarivate) and ClinicalTrials.gov. Studies involving adults with MSDs,  
37 regardless of publication status, language, or year, will be included. The scoping review will  
38 exclude studies using non-AI chatbots or human health coaches. Data extraction and  
39 synthesis will focus on demographic characteristics, chatbot methods, outcomes, and  
40 thematic analysis.

41  
42 **Ethics and dissemination:** Formal ethical approval is not required as this study involves  
43 neither human participants nor unpublished secondary data. Findings of the scoping review

44 will be disseminated through professional networks, conference presentations and  
45 publication in a scientific journal.

46

#### 47 **Strengths and limitations of this study**

48

- 49 ● We developed a search strategy with high sensitivity to retrieve studies
- 50 ● This scoping review will not exclude studies by publication status, language, or year  
51 of publication.

52

#### 53 **Introduction**

54

55 Musculoskeletal disorders (MSDs) are a significant global health concern, ranking as the  
56 second cause of non-fatal disability in 2020 and affecting over 1.63 billion individuals  
57 worldwide.<sup>1</sup> The burden of MSDs extends beyond physical limitations, often leading to  
58 substantial disability, with MSDs topping the list in terms of years lost to disability, according  
59 to the latest Global Burden of Disease report.<sup>2</sup> The enduring pain and disability associated  
60 with MSDs can also precipitate long-term psychological consequences.<sup>3</sup> Additionally, the  
61 considerable healthcare costs and the strain on workforce availability further compound  
62 the societal burden of these conditions.<sup>4</sup>

63

64 Amidst these challenges, artificial intelligence (AI) emerges as a transformative tool,  
65 reshaping how we process information and augmenting decision-making processes through  
66 problem-solving, reasoning, and learning. AI encompasses a range of methods, including  
67 machine learning, deep learning (DL), and natural language processing (NLP). Large  
68 Language Models (LLMs) represent a specific type of AI that employs DL and extensive  
69 datasets to comprehend, summarize, generate, and forecast new text-based content<sup>5-7</sup>. In  
70 the healthcare field, AI applications are diverse, ranging from machine learning algorithms  
71 that assist in diagnostic tools to LLMs that dialogue with patients.<sup>8</sup> This ability to engage in  
72 real-time dialogue with patients not only improves accessibility to healthcare services but  
73 also empowers patients by offering immediate, reliable information. Particularly, NLP  
74 models based on LLMs have gained prominence, enhancing their capabilities by generating  
75 and understanding human language through learned patterns rather than relying solely on  
76 predefined rules.<sup>9-10</sup> From these models, the use of Chatbots arise These systems engage  
77 users in dialogue, –typically online– and generate responses based on analyzed inputs and  
78 accessed knowledge.<sup>11</sup>

79

80 The use of chatbots has been reported in various aspects of health care, such as cancer<sup>12</sup>,  
81 behavioral change<sup>13</sup>, and psychiatry<sup>14</sup>, among others. Particularly in musculoskeletal care,  
82 chatbots have been studied in people with chronic pain<sup>15</sup>, shoulder arthroplasty<sup>16</sup>, and  
83 back pain<sup>17</sup>. However, to our knowledge, there is no evidence synthesis about the use of  
84 chatbots in this population.

85

86 This scoping review aims to provide an overview of the current and potential use of Artificial  
87 Intelligence-Powered Conversational Agents (chatbots) in people with MSD.

88

## 89 **Review questions**

- 90 1. In the context of MSDs, in which diseases and for what purpose have chatbots been  
91 used? (eg. medication reminders, exercise-based treatments reminders, education  
92 and motivation)
- 93 2. What clinical tools or conceptual frameworks are serving as benchmarks in training  
94 chatbots with artificial intelligence algorithms for application in clinical settings  
95 related to musculoskeletal conditions?
- 96 3. What outcomes are evaluated when implementing AI chatbots for the management  
97 of musculoskeletal disorders in clinical settings?

98

## 99 **Methods and analysis**

100

101 This scoping review will be developed following the Preferred Reporting Items for  
102 Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR).<sup>18</sup>

103

## 104 **Eligibility Criteria**

105

106 This review will include all primary studies that assess the use of AI chatbots in adults (older  
107 than 18 years) with a musculoskeletal disease in any setting. Musculoskeletal disorders  
108 refer to a diverse set of conditions affecting muscles, bones, joints, and related tissues, with  
109 symptoms that can vary in duration.

110 Articles will be excluded if they (1) used chatbots that did not incorporate AI (eg, chatbots  
111 and computerized coaches that were not conversational and without machine learning  
112 capabilities), (2) used human health coaches conversing with users through messaging  
113 platforms and (3) included participants that experience pain due to particular pathological  
114 causes (such as neurological disease, malignancy, inflammatory disease) will be excluded.

115

116 We will not exclude by status of publication, language, or year of publication.

117

118 Narrative reviews, letters to editors, or any non-original study will be excluded from this  
119 scoping review.

120

## 121 **Search Methods**

122

123 We will search the following databases from inception with no restrictions on date,  
124 language or publication status:

125

- 126 1. Medline (Ovid MEDLINE);
- 127 2. Embase (Ovid);
- 128 3. ISI Web of Science (wos; clarivate);
- 129 4. ClinicalTrials.gov ([www.clinicaltrials.gov](http://www.clinicaltrials.gov));

130 For detailed search strategies, see **Appendix 1**

131

## 132 **Selection of studies**

133

134 All identified records will be uploaded to the Rayyan web application after duplicates  
135 removal. Prior to the screening process, a pilot test of the proposed eligibility criteria will  
136 be performed using three to ten articles to solve any possible disagreements regarding the  
137 selection process. Two independent reviewers will then screen titles and abstracts, and  
138 further select the studies by reading the full text of potentially eligible studies. If there is a  
139 discrepancy in any step of the selection process a third reviewer will decide whether the  
140 study meets the eligibility criteria. The search results and the reasons for exclusions will be  
141 recorded and reported in a PRISMA-ScR flowchart.

142

## 143 **Data extraction process**

144

145 Two independent reviewers will extract data from the selected articles into a predefined  
146 template. For each study we will extract the Author, year of publication, country of origin,  
147 objectives, study population and sample size, intervention or exposure, measured  
148 outcomes, details of these outcomes, musculoskeletal disorder, and those key findings that  
149 relate to the question of this review. In case of discrepancies, a third reviewer will  
150 participate in this process.

151

## 152 **Collating, summarising and reporting the results**

153

154 The findings will be summarized in accordance with PRISMA-ScR guidelines, focusing on  
155 descriptive and thematic analysis. Descriptive elements will cover demographic  
156 characteristics, research country, publication details, and bibliometric data. This includes  
157 musculoskeletal diagnosis, description of the AI chatbot method, purpose of the AI chatbot,  
158 nature of the dataset (eg, size, data cleaning or preparation methods), the outcomes  
159 assessed, knowledge user engagement and healthcare setting of the study. Additionally, we  
160 may conduct further bibliometric analysis, such as cocitation networks among authors and  
161 countries using VosViewer.<sup>19</sup> Furthermore, a thematic summary will be provided to  
162 emphasize the main themes identified in the literature.

163

## 164 **Ethics and dissemination**

165

166 Formal ethical approval is not required as this study involves neither human participants  
167 nor unpublished secondary data. Findings of the scoping review will be disseminated  
168 through professional networks, conference presentations and publication in a scientific  
169 journal.

170

## 171 **Patient and public involvement**

172 The design of this scoping review protocol did not involve patients. However, patients'  
173 beliefs and experiences are central to the research question

174

175

## 176 References

177

- 178 1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global,  
179 regional, and national incidence, prevalence, and years lived with disability for 354  
180 diseases and injuries for 195 countries and territories, 1990-2017: a systematic  
181 analysis for the Global Burden of Disease Study 2017. *Lancet*. 2018 Nov  
182 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8.  
183 Erratum in: *Lancet*. 2019 Jun 22;393(10190):e44. doi: 10.1016/S0140-  
184 6736(19)31047-5.
- 185 2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and  
186 injuries in 204 countries and territories, 1990-2019: a systematic analysis for the  
187 Global Burden of Disease Study 2019. *Lancet*. 2020 Oct 17;396(10258):1204-1222.  
188 doi: 10.1016/S0140-6736(20)30925-9. Erratum in: *Lancet*. 2020 Nov  
189 14;396(10262):1562. doi: 10.1016/S0140-6736(20)32226-1.
- 190 3. Björnsdóttir SV, Jónsson SH, Valdimarsdóttir UA. Mental health indicators and  
191 quality of life among individuals with musculoskeletal chronic pain: a nationwide  
192 study in Iceland. *Scand J Rheumatol*. 2014;43(5):419-23. doi:  
193 10.3109/03009742.2014.881549.
- 194 4. Gaskin DJ, Richard P. The economic costs of pain in the United States. *J Pain*. 2012  
195 Aug;13(8):715-24. doi: 10.1016/j.jpain.2012.03.009.
- 196 5. Suleimenov IE, Vitulyova YS, Bakirov AS, Gabrielyan OA. Artificial Intelligence: what  
197 is it? *Proc 2020 6th Int Conf Comput Technol Appl*. 2020;22-5.  
198 <https://doi.org/10.1145/3397125.3397141>.
- 199 6. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. *Future*  
200 *Healthc J*. 2019 Jun;6(2):94-98. doi: 10.7861/futurehosp.6-2-94.
- 201 7. Russell SJ. Artificial intelligence a modern approach. Pearson Education, Inc.; 2010.
- 202 8. Alowais SA, Alghamdi SS, Alsuhebany N, Alqahtani T, Alshaya AI, Almohareb SN,  
203 Aldairem A, Alrashed M, Bin Saleh K, Badreldin HA, Al Yami MS, Al Harbi S, Albekairy  
204 AM. Revolutionizing healthcare: the role of artificial intelligence in clinical practice.  
205 *BMC Med Educ*. 2023 Sep 22;23(1):689. doi: 10.1186/s12909-023-04698-z. PMID:  
206 37740191; PMCID: PMC10517477.
- 207 9. Fralick M, Sacks CA, Muller D, Vining T, Ling E, Drazen JM, Hardin CC. Large Language  
208 Models. *NEJM Evid*. 2023 Aug;2(8):EVIDstat2300128. doi:  
209 10.1056/EVIDstat2300128.
- 210 10. Thirunavukarasu AJ, Ting DSJ, Elangovan K, Gutierrez L, Tan TF, Ting DSW. Large  
211 language models in medicine. *Nat Med*. 2023 Aug;29(8):1930-1940. doi:  
212 10.1038/s41591-023-02448-8.
- 213 11. Dahiya M. A tool of conversation: chatbot. *Int J Comput Sci Eng*. 2017 May  
214 30;5(5):158
- 215 12. Xu L, Sanders L, Li K, Chow JCL. Chatbot for Health Care and Oncology Applications  
216 Using Artificial Intelligence and Machine Learning: Systematic Review. *JMIR Cancer*.  
217 2021 Nov 29;7(4):e27850. doi: 10.2196/27850.

- 218 13. Aggarwal A, Tam CC, Wu D, Li X, Qiao S. Artificial Intelligence-Based Chatbots for  
219 Promoting Health Behavioral Changes: Systematic Review. *J Med Internet Res*. 2023  
220 Feb 24;25:e40789. doi: 10.2196/40789.
- 221 14. Gallegos C, Kausler R, Alderden J, Davis M, Wang L. Can Artificial Intelligence  
222 Chatbots Improve Mental Health?: A Scoping Review. *Comput Inform Nurs*. 2024 Jun  
223 27. doi: 10.1097/CIN.0000000000001155.
- 224 15. Andrews NE, Ireland D, Vijayakumar P, Burvill L, Hay E, Westerman D, Rose T,  
225 Schlumpf M, Strong J, Claus A. Acceptability of a Pain History Assessment and  
226 Education Chatbot (Dolores) Across Age Groups in Populations With Chronic Pain:  
227 Development and Pilot Testing. *JMIR Form Res*. 2023 Oct 6;7:e47267. doi:  
228 10.2196/47267.
- 229 16. Blasco JM, Navarro-Bosch M, Aroca-Navarro JE, Hernández-Guillén D, Puigcerver-  
230 Aranda P, Roig-Casasús S. A Virtual Assistant to Guide Early Postoperative  
231 Rehabilitation after Reverse Shoulder Arthroplasty: A Pilot Randomized Trial.  
232 *Bioengineering (Basel)*. 2024 Feb 2;11(2):152. doi:  
233 10.3390/bioengineering11020152.
- 234 17. Anan T, Kajiki S, Oka H, Fujii T, Kawamata K, Mori K, Matsudaira K. Effects of an  
235 Artificial Intelligence-Assisted Health Program on Workers With Neck/Shoulder  
236 Pain/Stiffness and Low Back Pain: Randomized Controlled Trial. *JMIR Mhealth*  
237 *Uhealth*. 2021 Sep 24;9(9):e27535. doi: 10.2196/27535.
- 238 18. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, Moher D, Peters MDJ,  
239 Horsley T, Weeks L, Hempel S, Akl EA, Chang C, McGowan J, Stewart L, Hartling L,  
240 Aldcroft A, Wilson MG, Garritty C, Lewin S, Godfrey CM, Macdonald MT, Langlois EV,  
241 Soares-Weiser K, Moriarty J, Clifford T, Tunçalp Ö, Straus SE. PRISMA Extension for  
242 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. *Ann Intern Med*. 2018  
243 Oct 2;169(7):467-473. doi: 10.7326/M18-0850.
- 244 19. van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for  
245 bibliometric mapping. *Scientometrics*. 2010 Aug;84(2):523-538. doi:  
246 10.1007/s11192-009-0146-3.

247

248

249 **Authors' contributions:** JGA descent conceived the idea of this project, established the  
250 research question and methodology, and led the development of the protocol. LV and HF  
251 contributed to the methods and gave meaningful contributions to the development and/or  
252 editing of the protocol. CMEL and JGA developed the search strategies. JOA and AP helped  
253 refine the protocol. All authors have approved the final version of the protocol.

254

255 **Funding statement:** This research received no specific grant from any funding agency in the  
256 public, commercial or not-for-profit sectors.

257

258 **Competing interests statement:** The authors have no conflicts of interest to declare.

259

260 **Appendix 1**

261

262 **Medline (Ovid)**

263

264 Ovid MEDLINE(R) ALL / PubMed(R) <1946 to Present>

265

266 1 "artificial intelligence".ti,ab. or exp Artificial Intelligence/ 226908

267 2 Chatbot\*.ti,ab. 1841

268 3 Musculoskeletal Diseases/ 15920

269 4 (bone or Orthopedic or Coxa or Osteochondritis or Hip or Knee or Ankle or Shoulder

270 or wrist or Hand or Spine or Back or Neck or Arthritis or limb or orthop\* or osteochondr\* or

271 Osteonecros\* or osteoporos\* or periarthriti\* or polymyalgia\* or scleroderma\* or

272 Spondylarthrit\* or sprain or fracture\* or sciatica).ti,ab. 2770180

273 5 3 or 4 2778974

274 6 1 or 2 227817

275 7 animals/ not humans/ 5218162

276 8 5 and 620840

277 9 8 not 7. 3565

278

279